

CITATION REPORT

List of articles citing

Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant *Pseudomonas aeruginosa* meningitis

DOI: 10.1007/s15010-020-01510-8
Infection, 2021, 49, 355-359.

Source: <https://exaly.com/paper-pdf/78022500/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. <i>Journal of Global Antimicrobial Resistance</i> , 2021 , 25, 346-350	3.4	1
8	Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections. <i>Current Opinion in Infectious Diseases</i> , 2021 , 34, 737-747	5.4	4
7	Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Meningitis. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa549	1	4
6	Current Perspectives on the Diagnosis and Management of Healthcare-Associated Ventriculitis and Meningitis.. <i>Infection and Drug Resistance</i> , 2022 , 15, 697-721	4.2	1
5	Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR <i>Pseudomonas aeruginosa</i> Infections: An Observational Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> ,	2.7	1
4	Healthcare-associated central nervous system infections. Publish Ahead of Print,		1
3	Off-Label Use of Ceftolozane/Tazobactam for the Successful Treatment of Healthcare-Associated Meningitis Caused by Extensively Drug-Resistant <i>Pseudomonas aeruginosa</i> in a Polytraumatized Patient. Case Report. 2022 , 5, 33		
2	The BloodBrain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults. 2022 , 11, 1843		0
1	Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams. 2023 , 21, 149-166		1